Natera loses patent ruling in NeoGenomics litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Natera Provides Update on Patent Litigation with NeoGenomics
August 29, 2025 8:18 AM EDTAUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc.
The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics v1.1 RaDaR test. Natera is evaluating its options, including an appeal and further enforcement with other patents.
Importantly, these patents are distinct from U.S. Patent No. 11,519,035 (the 035 patent), and yesterdays decision has no impact on the... More



